Literature DB >> 16944537

The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.

Vishal S Chandan1, William C Faquin, David C Wilbur, Kamal K Khurana.   

Abstract

BACKGROUND: CD57 (Leu7), a marker for natural killer lymphocytes, and glucose transporter-1 (GLUT-1), a facilitative cell surface glucose transport protein, are expressed in a wide spectrum of epithelial malignancies. The usefulness of CD57 and GLUT-1 immunostaining was evaluated as an adjunct to assist in the diagnosis of papillary carcinoma in fine-needle aspirations (FNAs) of the thyroid.
METHODS: Immunohistochemical staining for CD57 and GLUT-1 was performed on paraffin-embedded cell blocks of 50 thyroid FNA cases with the following cytologic diagnoses: 1) papillary carcinoma (15 cases); 2) atypical cytology, cannot exclude papillary carcinoma (14 cases); and 3) benign thyroid (21 cases).
RESULTS: Fourteen of 15 cases with an unequivocal diagnosis of papillary carcinoma were positive for CD57 and 1 case was negative for CD57. Tissue follow-up confirmed papillary carcinoma in all 15 cases. Of the 14 cases with a diagnosis of atypical cytology, cannot exclude papillary carcinoma, 6 cases were positive for CD57 and subsequent excision confirmed papillary carcinoma in all 6 cases. The remaining 8 cases negative for CD57 included surgically confirmed goiter (5 cases), adenoma (2 cases), and papillary carcinoma (1 case). The follicular cells in all 21 cases with a cytologic diagnosis of benign thyroid were negative for CD57. Histologic follow-up of these cases confirmed the benign cytologic diagnoses. GLUT-1 was negative in all cases. The sensitivity and specificity of CD57 was 91% and 100%, respectively.
CONCLUSIONS: CD57 immunostaining is a useful adjunct for the diagnosis of papillary thyroid carcinoma in cell block material. Although negative staining for CD57 does not completely exclude papillary carcinoma, positive staining aids in the accurate diagnosis of malignancy in cytomorphologically equivocal cases. GLUT-1 did not prove to be a useful marker in distinguishing papillary carcinomas. (c) 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16944537     DOI: 10.1002/cncr.22172

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Accuracy of fine needle aspiration biopsy processed by cytologic smear and cell block techniques for the diagnosis of lacrimal gland tumors: a study of 48 cases.

Authors:  Xiangning Wang; Jiang Qian; Yifei Yuan; Bo Ping; Liqing Feng; Yingwen Bi; Xiaping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Glucose transporter-1 (GLUT-1) immunoreactivity in benign, premalignant and malignant lesions of the gallbladder.

Authors:  Mateja Legan; Spela Tevžič; Ana Tolar; Boštjan Luzar; Vera Ferlan Marolt
Journal:  Pathol Oncol Res       Date:  2010-05-29       Impact factor: 3.201

3.  Diagnostic and prognostic markers in differentiated thyroid cancer.

Authors:  José M Gómez Sáez
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

4.  GLUT1 and ASCT2 Protein Expression in Papillary Thyroid Carcinoma Patients and Relation to Hepatitis C Virus: A Propensity-Score Matched Analysis.

Authors:  Afaf T Ibrahiem; Manal S Fawzy; Jawaher A Abdulhakim; Eman A Toraih
Journal:  Int J Gen Med       Date:  2022-03-14

5.  Comparison of Thin-Prep and cell block preparation for the evaluation of Thyroid epithelial lesions on fine needle aspiration biopsy.

Authors:  Husain A Saleh; Jamal Hammoud; Richard Zakaria; Aurang Zeb Khan
Journal:  Cytojournal       Date:  2008-03-25       Impact factor: 2.091

6.  Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.

Authors:  Husain A Saleh; Jining Feng; Farah Tabassum; Opada Al-Zohaili; Muji Husain; Tamara Giorgadze
Journal:  Cytojournal       Date:  2009-09-18       Impact factor: 2.091

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.